TriSalus Life Sciences, Inc. (TLSI)
NASDAQ: TLSI · IEX Real-Time Price · USD
5.55
0.00 (0.00%)
At close: Jul 19, 2024, 4:00 PM
5.43
-0.12 (-2.16%)
Pre-market: Jul 20, 2024, 9:28 AM EDT
TriSalus Life Sciences Revenue
TriSalus Life Sciences had revenue of $21.98M in the twelve months ending March 31, 2024, with 68.96% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $6.46M with 116.39% year-over-year growth. In the year 2023, TriSalus Life Sciences had annual revenue of $18.51M with 49.31% growth.
Revenue (ttm)
$21.98M
Revenue Growth
+68.96%
P/S Ratio
7.39
Revenue / Employee
$196,277
Employees
112
Market Cap
162.45M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 18.51M | 6.11M | 49.31% |
Dec 31, 2022 | 12.40M | 4.00M | 47.58% |
Dec 31, 2021 | 8.40M | - | - |
Dec 31, 2020 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionTLSI News
- 20 days ago - TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation - Business Wire
- 25 days ago - TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants - Business Wire
- 7 weeks ago - TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting - Business Wire
- 2 months ago - TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants - Business Wire
- 2 months ago - TriSalus Reports Q1 2024 Financial Results and Business Update - Business Wire
- 2 months ago - TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors - Business Wire
- 2 months ago - TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call - Business Wire
- 2 months ago - TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives - Business Wire